Prasol Chemicals: maiden post-IPO print — PAT +151% YoY as margins expand sharply

Prasol Chemicals' first results since its September 16, 2026 listing show standalone revenue from operations of ₹433.6 Cr for Q1 FY27, up 35.7% year-on-year from ₹319.6 Cr and 29.5% sequentially from ₹334.9 Cr. Standalone PAT more than doubled YoY to ₹61.0 Cr (+150.7% from ₹24.3 Cr) and rose 207.3% QoQ from ₹19.9 Cr, with EPS of ₹10.52 against ₹4.20 a year ago. The print runs well ahead of the on-plan revenue range of ₹250–280 Cr and the 8–9% volume growth guidance flagged in our pre-result preview — a clear beat on both counts, though the company has published no formal quarterly guidance in the filing itself. Street coverage remains thin post-listing; no formal Q1 FY27 consensus estimates turned up in a search, consistent with the neutral, low-coverage posture flagged pre-result, so this print becomes the first real anchor for analyst models.

Margin expansion is the bigger story than topline growth: net profit margin rose to 14.1% from 7.6% YoY (5.9% QoQ), and PBT margin to 19.3% from 10.3% YoY. Total expenses fell to 81.1% of revenue from operations from 90.0% a year ago. A meaningful share of that improvement traces to the 'changes in inventories' line, which swung from a ₹6.4 Cr drawdown a year ago to a ₹39.2 Cr net build this quarter — a roughly ₹45 Cr swing that mechanically reduces reported cost of goods sold when finished-goods/WIP stock is added rather than sold. Purchases of stock-in-trade also rose faster than revenue (20.1% of revenue vs 14.6% YoY), while employee costs and other expenses held broadly flat as a share of sales. Underlying margin quality should be read with the inventory build in mind rather than taken purely as pricing or cost-efficiency gains.

Standalone figures only — company has a single reportable segment (Speciality Chemicals) and files no consolidated statement

IPO-related costs of ₹0.26 Cr this quarter (₹3.2 Cr cumulative) capitalized under other current assets, to be charged to securities premium — no P&L impact

The Board that approved these results also accepted the retirement of Dr. Chitra Vaidya, Vice-President – R&D (effective September 30, 2026), and closed the trading window ahead of Q2/H1 FY27 results — both routine disclosures alongside the results filing. Separately, the company reported an insider-trading violation on September 24, 2026, a governance flag worth tracking for resolution in coming filings, though it carries no read-through to this quarter's P&L. Management has issued no separate press release or commentary with this filing, so there is no company framing to reconcile against the numbers.